References
- Cancer Research UK. 2017. Lung cancer mortality statistics.
- Cancer Research UK. Lung cancer incidence statistics | Cancer Research UK [Internet]. [accessed 2020 Oct 20]. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence#heading-Three.
- Dougall AL. 2014. Cancer: lung. In: Cambridge handbook of psychology, health and medicine, second edition. [place unknown]: Cambridge University Press; p. 605–606. doi: 10.1017/CBO9780511543579.138.
- Field JK, Duffy SW, Baldwin DR, et al. UK lung cancer RCT pilot screening trial : baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016;71(2):161–170. doi:10.1136/thoraxjnl-2015-207140.
- Church TR, . Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–1991. Black WC, Aberle DR, Berg CD. doi:10.1056/NEJMoa1209120.
- Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the national lung screening trial. N Engl J Med. 2013;369(10):920–931. doi:10.1056/nejmoa1208962.
- De Koning HJ, Van Der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513. doi:10.1056/NEJMoa1911793.
- Croatia first to introduce early screening for lung cancer. [accessed 2021 Jul 23]. https://echalliance.com/croatia-first-to-introduce-early-screening-for-lung-cancer/.
- Lung Cancer Screening in Poland Pilot Program Is Restarted After COVID-19 Lockdown. [accessed 2021 Jul 23]. https://www.iaslc.org/iaslc-news/ilcn/lung-cancer-screening-poland-pilot-program-restarted-after-covid-19-lockdown.
- 4-IN-THE-LUNG-RUN. [accessed 2021 Jul 23]. https://www.i-dna.org/4-in-the-lung-run/.
- NHS England. 2019. Targeted screening for lung cancer with low radiation dose computed tomography. 30.
- Meps D. Increasing the early diagnosis of lung cancer in Europe: an essential milestone to tackle the biggest cancer killer. https://www.longkankernederland.nl/media/1/Downloads/Brief-namens-54-organisaties-aan-leden-van-het-speciale-committee-vd-Europese-commissie-Beating-Cancer.pdf
- Snowsill T, Yang H, Griffin E, et al. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2018;22(69):1–276. doi:10.3310/hta22690.
- Tomonaga Y, ten Haaf K, Frauenfelder T, et al. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—a modelling study. Lung Cancer. 2018;121(2017):61–69. doi:10.1016/j.lungcan.2018.05.008.
- Shmueli A, Fraifeld S, Peretz T, et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. Value Health. 2013;16(6):922–931. doi:10.1016/j.jval.2013.05.007.
- Hofer F, Kauczor HU, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach. Lung Cancer. 2018;124:189–198. doi:10.1016/j.lungcan.2018.07.036.
- Goffin JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 2015;1(6):807–813. doi:10.1001/jamaoncol.2015.2472.
- Whynes DK. Could CT screening for lung cancer ever be cost effective in the United Kingdom? Cost Eff Resour Alloc. 2008;6(1):5. doi:10.1186/1478-7547-6-5.
- Hinde S, Crilly T, Balata H, et al. The cost-effectiveness of the Manchester ‘lung health checks’, a community-based lung cancer low-dose CT screening pilot. Lung Cancer. 2018;126:119–124. doi:10.1016/j.lungcan.2018.10.029.
- Bespalov A, Barchuk A, Auvinen A, et al. Cancer screening simulation models: a state of the art review. BMC Med Inform Decis Mak. 2021;21(1):359. doi:10.1186/s12911-021-01713-5.
- Willis M, Fridhammar A, Gundgaard J, et al. Comparing the cohort and Micro-Simulation modeling approaches in cost-effectiveness modeling of type 2 diabetes mellitus: a case study of the IHE diabetes cohort model and the economics and health outcomes model of T2DM. Pharmacoeconomics. 2020;38(9):953–969. doi:10.1007/s40273-020-00922-6.
- The National Institute for Health and Care (NICE). 2018. Guide to the methods of technology appraisal. (April 2013):1–93.
- Veronesi G, Baldwin DR, Henschke CI, et al. Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe. Cancers. 2020;12(6):1672. doi:10.3390/cancers12061672.
- Horeweg N, Van Der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the Nelson trial. Eur Respir J. 2013;42(6):1659–1667. doi:10.1183/09031936.00197712.
- Williamson S. National institute for health and care excellence. Lung Cancer: diagnosis and Management NICE Guideline. 2019 [accessed 2023 Dec 4]. https://www.nice.org.uk/guidance/ng122
- Office for National Statistics (ONS). Adult smoking habits in the UK. 2019. 2020 [Internet]. [accessed 2020 Nov 16]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsingreatbritain/2019.
- Field JK, Duffy SW, Baldwin DR, et al. The UK lung cancer screening trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):1–146. doi:10.3310/hta20400.
- World Health Organization - International Agency for Research on Cancer. Cancer Today | Estimated number of new cases in 2020, lung, both sexes, all ages [Internet]. [accessed 2020 Nov 5]. https://gco.iarc.fr/today/online-analysis-table.
- Bannister N, Broggio J. 2016. Cancer survival by stage at diagnosis for England (experimental statistics) - Office for National Statistics. [place unknown].
- McPherson I, Bradley NA, Govindraj R, et al. The progression of non-small cell lung cancer from diagnosis to surgery. Eur J Surg Oncol. 2020;46(10 Pt A):1882–1887. doi:10.1016/j.ejso.2020.08.013.
- Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190. doi:10.1200/JCO.2009.26.2543.
- Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. doi:10.1200/JCO.2012.44.2806.
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/nejmoa1801005.
- Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/nejmoa1809064.
- Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009.
- Latimer N. 2011. Nice dsu technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data report by the decision support unit. [Internet]. [accessed 2021 Apr 29]. https://www.nicedsu.org.uk
- Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9.
- Office for National Statistics (ONS). National life tables, UK [Internet]. [accessed 2020 Nov 16]. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables/current.
- Tramontano AC, Schrag DL, Malin JK, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the cancer care outcomes research and surveillance (CanCORS) study. Med Decis Making. 2015;35(3):371–387. doi:10.1177/0272989X15570364.
- Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518. doi:10.1111/j.1524-4733.2010.00700.x.
- Crosbie PA, Gabe R, Simmonds I, et al. Yorkshire lung screening trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk. BMJ Open. 2020;10(9):e037075. doi:10.1136/bmjopen-2020-037075.
- 2022/23 National Tariff Workbook. [accessed 2023 Nov 10]. https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/.
- Kennedy MPT, Hall PS, Callister MEJ. Factors affecting hospital costs in lung cancer patients in the United Kingdom. Lung Cancer. 2016;97:8–14. doi:10.1016/j.lungcan.2016.04.009.
- McGuire A, Martin M, Lenz C, et al. Treatment cost of non-small cell lung cancer in three european countries: comparisons across France, Germany, and England using administrative databases. J Med Econ. 2015;18(7):525–532. doi:10.3111/13696998.2015.1032974.
- Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899–907. doi:10.1177/0269216315595203.
- CPIH ANNUAL RATE 00: ALL ITEMS 2015 = 100 - Office for National Statistics. [accessed 2022 Sep 9]. https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/l55o/mm23.
- Vrdoljak E, Bodoky G, Jassem J, et al. Expenditures on oncology drugs and cancer mortality‐to‐incidence ratio in Central and Eastern Europe. Oncologist. 2019;24(1):e30–e37. doi:10.1634/theoncologist.2018-0093.
- Aberle DR, Adams AM, Berg CD, et al. The national lung screening trial research team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/nejmoa1102873.
- Group HE. 2022. Interim report on the cost-effectiveness of low dose computed tomography (LDCT) screening for lung cancer in high risk individuals about the UK National Screening committee (UK NSC). (March):1–80.
- Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745–758. [Internet]. [accessed 2023 Oct 31] doi:10.1007/S40273-018-0672-Z.
- Cleemput I, Neyt M, Van de Sande S, et al. Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Report 183C. D/2012/10.273/54
- Beyer T, Bidaut L, Dickson J, et al. What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging. 2020;20(1):38. [Internet]. [accessed 2021 Mar 10] doi:10.1186/s40644-020-00312-3.
- Rubio-Medrano C, Lamp J, Taguinod M, et al. 2016. Disparities and challenges in Access to lung cancer diagnostics and treatment across Europe - Lung Cancer Europe. [accessed 2023 Dec 4]. https://www.lungcancereurope.eu/2021/12/16/disparities-and-challenges-in-access-to-lung-cancer-diagnostics-and-treatment-across-europe/
- Basuki K. Europe’s beating cancer plan. [accessed 2023 Dec 4]. https://ec.europa.eu/commission/presscorner/detail/en/ip_21_342
- Cubi-Molla P, Garau M, Cubi-Molla P, et al. Resource allocation in public sector programmes: does the value of a life differ between governmental departments? OHE Research Paper, London: Office of Health Economics. https://www.ohe.org/publications/resource-allocation-public-sector-programmes-does-value-life-differ-between
- Han SS, ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer. 2017;140(11):2436–2443. doi:10.1002/ijc.30602.
- Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269–274. doi:10.1001/jamainternmed.2013.12738.
- Aberle DR, Black WC, Chiles C, et al. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial. J Thorac Oncol. 2019;14(10):1732–1742. doi:10.1016/j.jtho.2019.05.044.
- Leighl NB, Nirmalakumar S, Ezeife DA, et al. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41(41):1–12. [Internet]. [accessed 2023 Nov 22] doi:10.1200/EDBK_100028.
- Heuvelmans MA, Vonder M, Rook M, et al. Screening for early lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease (the big-3) using low-dose chest computed tomography: current evidence and technical considerations. J Thorac Imaging. 2019;34(3):160–169. doi:10.1097/RTI.0000000000000379.
- UN Department of Economics and Social Affairs. 2020. World Population Prospects - Population Division - United Nations [Internet]. [accessed 2020 Nov 5]. https://population.un.org/wpp/Download/Standard/Population/.
- Countrymeters. 2021. United Kingdom (UK) population (2021) live [Internet]. [accessed 2021 Jan 6]. https://countrymeters.info/en/United_Kingdom_(UK).